FDA Inspection 1119387 — OMRIX Biopharmaceuticals Ltd.
The FDA completed an inspection of OMRIX Biopharmaceuticals Ltd. on February 24, 2020 in Ramat Gan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- February 24, 2020
- Fiscal Year
- 2020
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Ramat Gan (Israel)